Sponsor or institution

Clinical trials and research at Miltenyi Biomedicine GmbH

• 12Clinical trials
• 17Countries

Newest trials

All recruiting trials (12)

• Zamtocabtagene autoleucel (MB-CART2019.1) for relapsed or refractory diffuse large B‑cell lymphoma in Japan

  This study will test a dual-target CAR T-cell therapy (MB-CART2019.1) that targets CD19 and CD20 in people in Japan whose diffuse large B‑cell lymphoma has returned or not responded after at least two prior therapies.

  Recruiting at 2 sites Phase 2 Miltenyi Biomedicine GmbH · Tokyo and 4 other locations · NCT07288879

• MB-CART2019.1 for refractory multiple sclerosis

  This trial will test a CAR T-cell therapy called MB-CART2019.1 to see if it is safe and helps adults with active, treatment‑resistant primary or secondary progressive multiple sclerosis.

  Recruiting Phase 1/2 Miltenyi Biomedicine GmbH · Berlin · NCT07178431

• Zamtocabtagene Autologous CAR-T for Autoimmune Diseases

  This early-phase study tests whether a patient’s own CAR-T cells (zamto-cel) can be safely given after standard therapy to people with lupus or systemic sclerosis.

  Recruiting Phase 1 Miltenyi Biomedicine GmbH · Milwaukee, Wisconsin · NCT06708845

• Zamtocabtagene autoleucel (MB-CART2019.1) for children and teens with relapsed or refractory mature B‑cell cancers

  This study will try one fresh infusion of MB-CART2019.1, a tandem CD20‑CD19 CAR‑T treatment, in children and adolescents (6 months to under 18 years) whose mature B‑cell cancers have come back or not responded to prior therapy.

  Recruiting at 2 sites Phase 2 Miltenyi Biomedicine GmbH · Paris, Boulevard Sérurier 48 and 4 other locations · NCT06508931

• Long-term follow-up for patients treated with Miltenyi CAR T therapies

  This study looks at how well Miltenyi CAR T cell therapies work and their long-term safety for patients, especially kids, who have already been treated.

  Recruiting at 2 sites Miltenyi Biomedicine GmbH · Berlin and 6 other locations · NCT06508775

• Genetically modified T cells for treating relapsed or refractory acute myeloid leukemia

  This study is testing a new treatment that uses specially modified T cells to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia.

  Recruiting Phase 1/2 Miltenyi Biomedicine GmbH · Leiden · NCT06424340

• Using CAR-T cells to treat autoimmune diseases

  This study is testing a new treatment using modified T cells to see if it can help people with autoimmune diseases by targeting and removing harmful B cells.

  Recruiting Phase 1/2 Miltenyi Biomedicine GmbH · Erlangen, Bavaria · NCT06347718

• Hematopoietic stem cell transplant using haploidentical donor grafts depleted of TCRα/β and CD45RA

  This pilot, single-arm study tests a specially prepared haploidentical stem cell graft in adults needing a transplant due to blood cancers when a matched donor isn’t available.

  Recruiting Miltenyi Biomedicine GmbH · Duarte, California · NCT06225050

• Treatment for patients with refractory systemic lupus erythematosus using MB-CART19.1

  This study is testing a new treatment called MB-CART19.1 to see if it can help people with tough-to-treat systemic lupus erythematosus feel better.

  Recruiting at 2 sites Phase 1/2 Miltenyi Biomedicine GmbH · Erlangen and 2 other locations · NCT06189157

• Long-term follow-up for patients treated with zamtocabtagene autoleucel

  This study follows patients who have received a specific CAR T-cell therapy for non-Hodgkin lymphoma to see how they do over time and if there are any long-term side effects.

  Recruiting at 10 sites Miltenyi Biomedicine GmbH · Gilbert, Arizona and 10 other locations · NCT06116110

• MB-CART2019.1 versus standard chemotherapy for relapsed/refractory diffuse large B‑cell lymphoma

  This study will test whether MB‑CART2019.1, a CD20/CD19 CAR‑T cell therapy, works better than standard chemotherapy for people with relapsed or refractory diffuse large B‑cell lymphoma who are not eligible for high‑dose chemotherapy and autologous stem cell transplant.

  Recruiting at 39 sites Phase 2 Miltenyi Biomedicine GmbH · Graz and 50 other locations · NCT04844866

• CAR-T cell therapy for relapsed or refractory DLBCL

  This study is testing a new CAR-T cell therapy to see if it can help people with tough-to-treat diffuse large B cell lymphoma feel better after other treatments haven’t worked.

  Recruiting at 30 sites Phase 2 Miltenyi Biomedicine GmbH · Birmingham, Alabama and 31 other locations · NCT04792489

Quick answers

How many clinical trials run by Miltenyi Biomedicine GmbH are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 17 countries. The most sites are in Germany (6 trials), United States (4 trials), Netherlands (3 trials), France (2 trials), Italy (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 4, Phase 2: 4, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →